Entering text into the input field will update the search result below

Atea Pharmaceuticals: Hoping Its COVID Efforts Are Still Relevant

Sep. 27, 2023 1:43 AM ETAtea Pharmaceuticals, Inc. (AVIR)


  • Atea Pharmaceuticals is a small biotech company with a focus on developing antiviral therapeutics for viral infections.
  • Their lead product candidate, AT-527, is currently in a Phase III study for the treatment of COVID-19 in high-risk patients.
  • Atea Pharmaceuticals also has a HCV program entering Phase 2 development, and the company's net cash currently dwarfs its market capitalization.
  • Is Atea Pharmaceuticals a good investment at just over three bucks a share? An analysis follows below on this Busted IPO.
  • Looking for a helping hand in the market? Members of The Busted IPO Forum get exclusive ideas and guidance to navigate any climate. Learn More »

Triple Virus Lung Infection

wildpixel/iStock via Getty Images

The future is not just about startups but stay-ups; anyone can start but it takes those who can stand the test of time to stay relevant.”― Bernard Kelvin Clive

Today, we put Atea Pharmaceuticals, Inc. (

Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum. Try a free 2-week trial today by clicking on our logo below!

This article was written by

Busted IPO Forum profile picture

The Busted IPO Forum is an investing group led by Bret Jensen, Chief Investment Strategist of Simplified Asset Management. Along with his team of analysts, Bret focuses on stocks that have been public for 18 months to 6 years, and that are significantly under their offering price.

The Busted IPO Forum: A model stock portfolio of attractive busted IPOs, trade alerts, deep dive analysis, a weekly option play idea and live chat.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You


Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About AVIR

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on AVIR

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.